help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 13, No. suppl_3, 1-3, May 2008; doi:10.1634/theoncologist.13-S3-1
© 2008 AlphaMed Press

This Article
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aapro, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aapro, M. S.

Editorial: Anemia Management with Erythropoiesis-Stimulating Agents: A Risk–Benefit Update

Matti S. Aapro

Multidisciplinary Oncology Institute, Genolier, Switzerland

Key Words. Anemia • Erythropoiesis-stimulating agents • Erythropoietin receptors • Risk–benefit

Correspondence: Matti S. Aapro, M.D., IMO Clinique de Genolier, 1 Route du Muids, 1272 Genolier, Switzerland. Telephone: 41223669106; Fax: 41223669131; e-mail: maapro{at}genolier.net

Received December 10, 2007; accepted for publication January 7, 2008.

Disclosure: M.A. has received study grants and honoraria for consultancy and/or is on the speakers bureau of Amgen, Johnson and Johnson, Ortho Biotech, Sandoz, and Roche. No other potential conflicts of interest were reported by the author, planners, reviewers, or staff managers of this article.

More than 80% of cancer patients undergoing chemotherapy develop anemia (hemoglobin [Hb] level <12 g/dl), and the need for blood transfusion is frequent [1]. Erythropoiesis-stimulating agents (ESAs) were developed with the aim of reducing transfusion dependence, and meta-analyses of clinical trials confirm that they have been highly successful in achieving this [2, 3].

The systematic review by Bohlius et al. [2] incorporated data from a total of 9,353 cancer patients, with tumors including those of the breast, lung, and gastrointestinal tract, treated in 57 trials. Treatment with epoetin or darbepoetin significantly reduced the need for transfusion (relative risk, 0.64; 95% confidence interval, 0.60–0.68), and the chance of achieving a hematologic response was consistent across tumor types.

These findings were supported by the 2006 analysis of the Agency for Healthcare Research and Quality [3]. Both meta-analyses noted a slightly higher risk for venous thromboembolic events (VTEs) in patients administered epoetin or darbepoetin, and were suggestive that this risk was associated with higher Hb levels.

ESAs have the advantage of avoiding the fluctuations in Hb level associated with RBC transfusions, as well as reducing the risks for disease transmission and the cardiac and hepatic consequences of iron overload (an issue in patients with hematologic malignancies) [4]. Furthermore, under controlled conditions, RBCs can be stored for up to 42 days prior to transfusion, and this is a potential source of problems [5]. Indeed, in retrospective studies, a correlation was found between the duration of RBC storage and the morbidity and mortality rates after transfusion [5–8]. Variations can occur in stored RBCs over time, which may include changes in RBC-dependent vasoregulatory function and S-nitrosohemoglobin (SNO-Hb), and RBC deformability [5]. Changes can occur even soon after blood collection, where SNO levels (and their physiological correlate RBC-dependent vasodilation) become depressed [5]. Thus, changes may occur in stored RBCs that impact the function of the RBCs and can affect clinical outcomes. In the 13 years since recombinant erythropoietin was first approved for the treatment of cisplatin-related anemia, around four million patients have been treated with ESAs; and their quality of life (when symptoms have been anemia related) has been greatly improved as a consequence (Fig. 1) [9–14].


Figure 1
View larger version (22K):
[in this window]
[in a new window]

  		Figure 1. Anemia management timeline [9, 11–14].

Abbreviation: ESA, erythropoiesis-stimulating agent.

 
Anemia is one of several factors that contribute to tumor hypoxia, which reduces sensitivity to radiotherapy [15]. However, Hb levels >14 g/dl can actually be associated with reduced tumor oxygenation. This suggests (as discussed in this issue by Peter Vaupel [16]) that Hb levels need to be regulated around a target value of 12 g/dl in cancer patients. This is the level at which the maximum benefits in terms of gains in quality of life have been documented [16]. Jean-Philippe Spano and David Khayat discuss in further detail, in this issue, the risk considerations of blood transfusions versus ESAs and the impact anemia has on the patient's quality of life [18].

Some recent studies have suggested a link between the use of ESAs in certain clinical settings and reduced survival [19–23]. It is important to realize that this is mainly in nonapproved indications, including in patients who are not anemic or who are not undergoing chemotherapy, sometimes in studies where survival was not a primary endpoint or that were truncated for other reasons. There have also been reports linking the purported presence of erythropoietin receptors on tumor cells to disease progression [24]. The nature of these studies is discussed in detail in this volume in papers by Pere Gascón [25] and Joachim Fandrey [26].

As mentioned above, there has also been concern about the higher risk for VTEs when ESAs are administered, especially to patients who already have relatively high Hb levels. These concerns are considered in a paper by Mario Dicato [27].

A working party of the European Organization for Research and Treatment of Cancer met in September 2007 to update the Organization's 2006 guidelines on use of ESAs [28]. The changes to the 2006 guidelines are highlighted in this issue.

In conclusion, when ESAs are used within label and the updated guidelines, in cancer patients receiving chemotherapy to correct anemia (only if associated with symptoms) to a target Hb level of about 12 g/dl, they have a favorable benefit–risk ratio, as recently confirmed by the European Medicines Agency [29].


   REFERENCES
Top
 References
 

  1. Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293–2306.[CrossRef][Medline]
  2. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708–714.[Abstract/Free Full Text]
  3. Seidenfeld J, Piper M, Bohlius J et al. Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment. Comparative Effectiveness Review No. 3. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Evidence-based Practice Center under Contract No. 290-02-0026.). 2006, 5, Agency for Healthcare Research and Quality, Rockville, MD, Available at http://effectivehealthcare.ahrq.gov/repFiles/EPO%20Final.pdf. Accessed April 10, 2008.
  4. Goodnough LT. Erythropoietin therapy versus red cell transfusion. Curr Opin Hematol 2001;8:405–410.[CrossRef][Medline]
  5. Bennett-Guerrero E, Veldman TH, Doctor A et al. Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A 2007;104:17063–17068.[Abstract/Free Full Text]
  6. Leal-Noval SR, Jara-López I, García-Garmendia JL et al. Influence of erythrocyte concentrate storage time on postsurgical morbidity in cardiac surgery patients. Anesthesiology 2003;98:815–822.[CrossRef][Medline]
  7. Purdy FR, Tweeddale MG, Merrick PM. Association of mortality with age of blood transfused in septic ICU patients. Can J Anaesth 1997;44:1256–1261.[Medline]
  8. Zallen G, Offner PJ, Moore EE et al. Age of transfused blood is an independent risk factor for postinjury multiple organ failure. Am J Surg 1999;178:570–572.[CrossRef][Medline]
  9. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865–2874.[Abstract/Free Full Text]
  10. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072–1079.[CrossRef][Medline]
  11. Ludwig H, Fritz E, Kotzmann H et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693–1699.[Abstract]
  12. Abels RI. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol 1992;87(suppl 1):4–11.[Medline]
  13. Henry DH. Clinical application of recombinant erythropoietin in anemic cancer patients. Hematol Oncol Clin North Am 1994;8:961–973.[Medline]
  14. O'Shaughnessy JA, Vukelja SJ, Holmes FA et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 2005;5:439–446.[Medline]
  15. Harrison LB, Shasha D, White C et al. Radiotherapy-associated anemia: The scope of the problem. The Oncologist 2000;5(suppl 2):1–7.[Abstract/Free Full Text]
  16. Vaupel P. Hypoxia and aggressive tumor phenotype: Implications for therapy and prognosis. The Oncologist 2008;13(suppl 3):21–26.[Abstract/Free Full Text]
  17. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888–895.[CrossRef][Medline]
  18. Spano JP, Khayat D. Treatment options for anemia, taking risks into consideration: Erythropoiesis-stimulating agents versus transfusions. The Oncologist 2008;13(suppl 3):27–32.[Abstract/Free Full Text]
  19. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;23:5960–5972.[Abstract/Free Full Text]
  20. Henke M, Laszig R, Rübe C et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255–1260.[CrossRef][Medline]
  21. Danish Head and Neck Cancer Group. Interim Analysis of DAHANCA 10. Available at http://www.dahanca.dk/get_media_file.php?mediaid=125. Accessed September 21, 2007.
  22. Wright JR, Ung YC, Julian JA et al. Randomized, double blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027–1032.[Abstract/Free Full Text]
  23. Smith RE Jr, Aapro MS, Ludwig H et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040–1050.[Abstract/Free Full Text]
  24. Henke M, Mattern D, Pepe M et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24:4708–4713.[Abstract/Free Full Text]
  25. Gascón P. Safety update on erythropoiesis-stimulating agents: Trials within and outside the accepted indications. The Oncologist 2008;13(suppl 3):4–10.[Abstract/Free Full Text]
  26. Fandrey J. Erythropoietin receptors on tumor cells: What do they mean? The Oncologist 2008;13(suppl 3):16–20.[Abstract/Free Full Text]
  27. Dicato M. Venous thromboembolic events and erythropoiesis-stimulating agents: An update. The Oncologist 2008;13(suppl 3):11–15.[Abstract/Free Full Text]
  28. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258–270.[CrossRef][Medline]
  29. EMEA (European Medicines Agency). Post-authorisation Evaluation of Medicines for Human Use. Public Statement: Epoetins and the Risk of Tumour Growth Progression and Thromboembolic Events in Cancer Patients and Cardiovascular Risks in Patients With Chronic Kidney Disease. 2007, 10, 23, London, Available at http://www.emea.europa.eu/pdfs/human/press/pus/49618807en.pdf. Accessed April 10, 2008.




This Article
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aapro, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aapro, M. S.

HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS